RET / MET / NTRK inhibitors

Mechanism

융합·증폭 의존 종양에서 선택적 TKI. RET(셀퍼카티닙), MET exon14(카프마티닙), NTRK 융합(라로트렉티닙)은 tumor-agnostic 승인이 있습니다.

Medicinal chemistry

용매 노출 치환기로 off-target KDR/VEGFR을 줄인 2세대 RET, type Ib MET, 매크로사이클 NTRK가 대표 케모타입입니다.

Structure families

• RET / MET / NTRK oncogene TKI series8 compounds

Key drugs · payloads

• Capmatinib (Tabrecta)Drug
• Entrectinib (Rozlytrek)Drug
• Larotrectinib (Vitrakvi)Drug
• Selpercatinib (Retevmo)Drug
• Pralsetinib (Gavreto)Drug
• Repotrectinib (Augtyro)Drug
• Tepotinib (Tepmetko)Drug

BioMoa